Labaran Masana'antu
-
CagriSema na haɓakar asarar nauyi a asibiti a China
A ranar 5 ga Yuli, Novo Nordisk ya ƙaddamar da gwajin gwaji na asibiti na kashi III na allurar CagriSema a kasar Sin, manufarsa ita ce kwatanta aminci da ingancin allurar CagriSema tare da semeglutide a cikin marasa lafiya masu kiba da kiba a China.CagriSema allurar dogon aiki ce ...Kara karantawa
